ArticleAnimal models and experimental medicine2026
A humanized NOG-EXL mouse model for producing severe fever with thrombocytopenia syndrome virus-reactive human antibodies.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHumanized mouse models are essential for studying the human immune response and antibody development. However, conventional models show limited B cell maturation and antigen-specific humoral responses. To overcome these limitations, we used the NOG-EXL mice expressing human interleukin 3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to enhance myeloid and B-cell lineage differentiation.
methodsHuman CD34
resultsTwelve weeks after transplantation of HSCs into NOG-EXL mice, they exhibited robust engraftment of human leukocytes, including T, B, and dendritic cells, compared to NOG mice. Unlike NOG mice, humanized NOG-EXL mice exhibited an increase in human IgG levels, indicating the production of human antibody responses to antigens. Humanized NOG-EXL mice were immunized twice every 2 weeks with inactivated SFTSV, and antigen-specific human antibodies against the virus were detected in the mouse sera by ELISA. Sera from SFTSV-immunized humanized mice demonstrated neutralizing activity against SFTSV, confirming the induction of functional virus-specific neutralizing antibodies. Antigen-binding IgG-positive human B cells were isolated from mouse splenocytes using recombinant protein probes.
conclusionThis model provides a valuable platform for evaluating humoral immunity and isolating B cells using high-affinity human monoclonal antibodies without genetic engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.